CAD participants had higher levels of matrilysin (MMP‐7), galectin‐4 (GAL4) and plasminogen activator inhibitor 1 (PAI), and lower levels of peptidoglycan recognition protein 1 (PGLYRP1). Here, PGLYRP1 is linked to coronary artery disorder.